P6561Mechanism of ultra-low LDL-C and platelets - insights from Tangier disease patients and patients on PCSK9 inhibitor therapy
Lisa Pasterk(University of Zurich), Jürg H. Beer(University of Zurich), Pascal Koepfli(Kantonsspital Baden), Hans-Rudolf Schmid(Kantonsspital Baden), T F Luescher(Imperial College London), M Liu(Kantonsspital Baden), Giovanni G. Camici(University of Zurich), Michael Egloff(Kantonsspital Baden), S Meier(Kantonsspital Baden), S Gobbato(University of Zurich), Marcel Frick(Kantonsspital Baden), Nicole R. Bonetti(University Hospital Zurich)
Cited by 0
Related Papers
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England
|The Lancet|2020|747
Impact of Oxidative Stress on the Heart and Vasculature
|Journal of the American College of Cardiology|2017|603
Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation
|Journal of the American College of Cardiology|2019|228
Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood–brain barrier integrity: a translational study
|European Heart Journal|2019|102
Sirtuin 5 as a novel target to blunt blood–brain barrier damage induced by cerebral ischemia/reperfusion injury
|International Journal of Cardiology|2018|100